ArticlePloS one2026
Salmonella enterica persister cells exhibit distinct susceptibility profiles following exposure to human serum and macrophages.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salmonella enterica, particularly non-typhoidal serovars (NTS), is a leading cause of foodborne illness, with invasive infections posing high mortality risks in developing countries. Fluoroquinolones and third-generation cephalosporins, such as ceftazidime (CAZ), are used to treat severe infections, yet they are facing concerning rates of antimicrobial resistance. Furthermore, recalcitrant and/or persistent infections are often linked to persister cells, a phenotype that enables cells to survive in the presence of high concentrations of antibiotics. Although persisters are associated with chronic infections, their interactions with the human immune system, particularly serum resistance and opsonophagocytosis, are not well understood. Here, three NTS isolates from the food protein chain (S45, S48, and 4SA(2)) were used. Persister cells were selected by exposure to CAZ concentration 100 times higher than the minimum inhibitory concentration and then assessed for serum resistance, opsonophagocytosis, and intracellular survival in primary human macrophages. The isolates exhibited heterogeneous persister fractions (1.06%-39.55% survival after 72h of CAZ exposure). Persisters exhibited equal or greater serum resistance than regular cells. Isolate 4SA(2) proliferated in 100% human serum, with persister-derived cells showing higher growth rates. Following opsonization, serum-resistant persisters of all isolates were phagocytosed at significantly higher rates than serum-resistant regular cells. Intracellular survival varied: S45 persisters proliferated post-internalization; S48 persisters and regulars were eradicated; 4SA(2) showed no phenotype difference. Complement enhanced the intracellular survival of S45 but not S48 or 4SA(2). Despite having different intracellular outcomes, Salmonella persisters showed higher levels of opsonophagocytosis and serum resistance. These findings suggest that cell surface modifications may facilitate host cell uptake and contribute to antimicrobial treatment failure and long-term infection. The phenotypic diversity among isolates underscores the importance of considering persister heterogeneity and host-pathogen immune interactions in order to understand recalcitrant infection dynamics and design more effective therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.